Stryker Corp. (SYK) Director Ronda E. Stryker Sells 6,000 Shares of Stock
Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 6,000 shares of the firm’s stock in a transaction on Wednesday, September 28th. The stock was sold at an average price of $116.68, for a total value of $700,080.00. Following the completion of the transaction, the director now owns 193,142 shares in the company, valued at $22,535,808.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Stryker Corp. (NYSE:SYK) opened at 117.31 on Thursday. Stryker Corp. has a one year low of $86.68 and a one year high of $123.55. The company has a market cap of $43.91 billion, a PE ratio of 27.65 and a beta of 0.71. The stock’s 50 day moving average price is $114.72 and its 200-day moving average price is $113.32.
Stryker Corp. (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 21st. The medical technology company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.02. The firm had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.79 billion. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. On average, analysts expect that Stryker Corp. will post $5.76 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be given a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 1.30%. The ex-dividend date of this dividend is Wednesday, September 28th. Stryker Corp.’s dividend payout ratio (DPR) is currently 35.85%.
Several analysts recently commented on SYK shares. Canaccord Genuity reaffirmed a “buy” rating and set a $130.00 price objective on shares of Stryker Corp. in a research note on Sunday, July 24th. Zacks Investment Research raised Stryker Corp. from a “hold” rating to a “buy” rating and set a $130.00 price objective on the stock in a research note on Tuesday, June 21st. Guggenheim started coverage on Stryker Corp. in a research note on Wednesday, June 8th. They set a “buy” rating and a $134.00 price objective on the stock. Brean Capital reaffirmed a “buy” rating and set a $125.00 price objective (up previously from $121.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Finally, Jefferies Group reaffirmed a “hold” rating and set a $120.00 price objective (up previously from $113.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $114.91.
Hedge funds have recently bought and sold shares of the stock. LSV Asset Management acquired a new position in shares of Stryker Corp. during the second quarter worth approximately $107,000. Global X Management Co. LLC boosted its position in shares of Stryker Corp. by 235.8% in the second quarter. Global X Management Co. LLC now owns 994 shares of the medical technology company’s stock worth $119,000 after buying an additional 698 shares during the last quarter. Carroll Financial Associates Inc. boosted its position in shares of Stryker Corp. by 78.0% in the second quarter. Carroll Financial Associates Inc. now owns 1,086 shares of the medical technology company’s stock worth $130,000 after buying an additional 476 shares during the last quarter. CWM LLC acquired a new position in shares of Stryker Corp. during the second quarter worth approximately $150,000. Finally, SevenBridge Financial Group LLC acquired a new position in shares of Stryker Corp. during the second quarter worth approximately $197,000. Hedge funds and other institutional investors own 75.49% of the company’s stock.
About Stryker Corp.
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.